onr:"swepub:oai:DiVA.org:liu-47472"
Search: onr:"swepub:oai:DiVA.org:liu-47472" > Rufinamide :
- 1 of 1
- Previous record
- Next record
- To hitlist
- Pålhagen, SvenLinköpings universitet,Hälsouniversitetet,Geriatrik (author)
Rufinamide : A double-blind, placebo-controlled proof of principle trial in patients with epilepsy
- Article/chapterEnglish2001
Publisher, publication year, extent ...
- 2001
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:liu-47472
- https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-47472URI
- https://doi.org/10.1016/S0920-1211(00)00185-6DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Objective: This was the first proof of principle clinical trial assessing the efficacy and safety of rufinamide as adjunctive therapy in epileptic patients. The pharmacokinetic (PK) profile of rufinamide was also determined. Methods: Fifty patients with diagnoses of partial or primary generalized tonic-clonic seizures were enrolled in this 28-day double-blind, placebo-controlled, weekly rising dose (400-1600 mg/day) trial. PK profiles were obtained after administration of single-dose rufinamide prior to and after the Double-blind phase. Results: In the evaluable patient population, seizure frequency decreased by 41% in the rufinamide group and increased by 52% in the placebo group (P = 0.040). Thirty-nine percent (39%) of rufinamide-treated and 16% of placebo-treated patients experienced reduction in seizure frequency of at least 50% relative to baseline (P = 0.096). Safety: Treatment-emergent adverse events (AEs) consisted mainly of neurologic signs and symptoms commonly associated with antiepileptic drugs (AEDs). Pharmacokinetics: At steady state, rufinamide reached a peak plasma concentration with a mean time (Tmax) of 3.4 h and a mean half-life (t1/2) of 7.3 h. No autoinduction of rufinamide metabolism occurred. Rufinamide did not influence the plasma concentration of carbamazepine, phenytoin or valproate when added to these single AED regimens. Conclusion: Rufinamide has been shown, in this proof of principle trial, to be safe and effective in reducing seizure frequency in epileptic patients with no relevant influence on the metabolism of other AEDs. © 2001 Elsevier Science B.V.
Subject headings and genre
- AED
- Antiepileptic agents
- Pharmacokinetics
- Rufinamide
- Seizures
- MEDICINE
- MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
- Canger, R.Centro Per l'Epilessia, Ospedale S. Paolo, Milan, Italy (author)
- Henriksen, O.National Centre for Epilepsy, Postbox 900, N-1337 Sandvika, Norway (author)
- Van, Parys J.A.Van Parys, J.A., Instituut Voor Epilepsie Bestrijding, Heemstede, Netherlands (author)
- Riviere, M.-E.Rivière, M.-E., CRD, S-27.7.061, Novartis Pharma AG, CH-4002 Basel, Switzerland (author)
- Karolchyk, M.A.CRD, S-27.7.061, Novartis Pharma AG, CH-4002 Basel, Switzerland (author)
- Linköpings universitetHälsouniversitetet (creator_code:org_t)
Related titles
- In:Epilepsy Research43:2, s. 115-1240920-12111872-6844
Internet link
Find in a library
- Epilepsy Research (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Pålhagen, Sven
- Canger, R.
- Henriksen, O.
- Van, Parys J.A.
- Riviere, M.-E.
- Karolchyk, M.A.
- Articles in the publication
- Epilepsy Researc ...
- By the university
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
